Younger Females' Cancer Incidence Increases Significantly In China
Tops COVID As Public Health Concern
Executive Summary
Latest data show a worrying public health trend that remains the top health concern in China despite surging COVID infections.
You may also be interested in...
Will Yabao Help Lupin’s Attempts To Scale The Great Wall?
With the Yabao partnership, Lupin builds on a toehold gained through the Foncoo tie-up as it attempts to scale the market behind the Great Wall of China. Scrip takes a look at possible approaches and potential of the partnership
CEO Podcast: Hengrui's US Subsidiary's CEO, CMO On Chinese Pharma Going Global
While many pharma firms in China choose to partner with US companies, Jiangsu Hengrui is relying on itself to go global. The Chinese pharma giant is betting on its newly established US subsidiary Luzsana in a major move to make its wide-ranging products more available, accessible and affordable to patients in the US and the rest of the world.
China's mRNA Shot Shows Benefits Over Older COVID Vaccines
Home-grown Chinese mRNA COVID-19 vaccines are more effective than domestic inactivated virus-based shots, new trial results show.